In trading on Wednesday, shares of Iovance Biotherapeutics Inc (Symbol: IOVA) entered into oversold territory, hitting an RSI reading of 26.9, after changing hands as low as $7.0602 per share.
In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Iovance Biotherapeutics (IOVA – Research Report). The company’s shares closed yesterday at $6.07.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback